The efficacy of tamsulosin 0.4 mg when tamsulosin 0.2 mg is insufficient for benign prostatic hyperplasia in Korean patients.

IF 2.1 3区医学 Q2 UROLOGY & NEPHROLOGY

Investigative and Clinical Urology Pub Date : 2026-03-01 DOI:10.4111/icu.20250569

Younsoo Chung, Seong Jin Jeong, Sang Hun Song, Sung Kyu Hong

{"title":"The efficacy of tamsulosin 0.4 mg when tamsulosin 0.2 mg is insufficient for benign prostatic hyperplasia in Korean patients.","authors":"Younsoo Chung, Seong Jin Jeong, Sang Hun Song, Sung Kyu Hong","doi":"10.4111/icu.20250569","DOIUrl":null,"url":null,"abstract":"Purpose: This study evaluated the clinical impact of escalating tamsulosin dosage from 0.2 to 0.4 mg in men with benign prostatic hyperplasia (BPH) who exhibited inadequate responses to the lower dose.Materials and methods: A retrospective review was performed on 57 patients treated at Seoul National University Bundang Hospital in 2022. Uroflowmetry parameters, International Prostate Symptom Score (IPSS), and postvoid residual volume (PVR) were compared before and after dose escalation. Subgroup analysis was conducted by age, prostate volume, and concomitant 5-alpha-reductase inhibitor use.Results: The mean maximum urinary flow rate value improved significantly from 14.4 to 17.7 mL/s (p<0.001), with consistent benefits across subgroups. No significant changes were observed in IPSS or PVR overall, although PVR decreases were significant in prostates >50 mL.Conclusions: Escalating tamsulosin from 0.2 to 0.4 mg can meaningfully improve urinary flow in certain BPH patients, particularly those with larger prostates or concomitant 5-alpha-reductase inhibitor therapy.","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"67 2","pages":"186-191"},"PeriodicalIF":2.1000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12956770/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Investigative and Clinical Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4111/icu.20250569","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study evaluated the clinical impact of escalating tamsulosin dosage from 0.2 to 0.4 mg in men with benign prostatic hyperplasia (BPH) who exhibited inadequate responses to the lower dose.

Materials and methods: A retrospective review was performed on 57 patients treated at Seoul National University Bundang Hospital in 2022. Uroflowmetry parameters, International Prostate Symptom Score (IPSS), and postvoid residual volume (PVR) were compared before and after dose escalation. Subgroup analysis was conducted by age, prostate volume, and concomitant 5-alpha-reductase inhibitor use.

Results: The mean maximum urinary flow rate value improved significantly from 14.4 to 17.7 mL/s (p<0.001), with consistent benefits across subgroups. No significant changes were observed in IPSS or PVR overall, although PVR decreases were significant in prostates >50 mL.

Conclusions: Escalating tamsulosin from 0.2 to 0.4 mg can meaningfully improve urinary flow in certain BPH patients, particularly those with larger prostates or concomitant 5-alpha-reductase inhibitor therapy.

Abstract Image

查看原文本刊更多论文

当坦索罗辛0.2 mg不足以治疗韩国患者的良性前列腺增生时，0.4 mg坦索罗辛的疗效。

目的：本研究评估坦索罗辛剂量从0.2 mg增加到0.4 mg对良性前列腺增生（BPH）患者的临床影响，这些患者对较低剂量反应不足。材料与方法：对2022年在首尔大学盆唐医院接受治疗的57例患者进行回顾性分析。比较剂量递增前后尿流仪参数、国际前列腺症状评分（IPSS）和空隙后残留体积（PVR）。根据年龄、前列腺体积和同时使用5- α -还原酶抑制剂进行亚组分析。结果：平均最大尿流率值从14.4 mL/s显著提高到17.7 mL/s （p50 mL）。结论：坦索罗辛从0.2 mg增加到0.4 mg可以显著改善某些前列腺增生患者的尿流，特别是那些前列腺较大或同时接受5- α -还原酶抑制剂治疗的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Investigative and Clinical Urology Medicine-Urology

CiteScore

4.10

自引率

4.30%

发文量

审稿时长

4 weeks

期刊介绍： Investigative and Clinical Urology (Investig Clin Urol, ICUrology) is an international, peer-reviewed, platinum open access journal published bimonthly. ICUrology aims to provide outstanding scientific and clinical research articles, that will advance knowledge and understanding of urological diseases and current therapeutic treatments. ICUrology publishes Original Articles, Rapid Communications, Review Articles, Special Articles, Innovations in Urology, Editorials, and Letters to the Editor, with a focus on the following areas of expertise: • Precision Medicine in Urology • Urological Oncology • Robotics/Laparoscopy • Endourology/Urolithiasis • Lower Urinary Tract Dysfunction • Female Urology • Sexual Dysfunction/Infertility • Infection/Inflammation • Reconstruction/Transplantation • Geriatric Urology • Pediatric Urology • Basic/Translational Research One of the notable features of ICUrology is the application of multimedia platforms facilitating easy-to-access online video clips of newly developed surgical techniques from the journal''s website, by a QR (quick response) code located in the article, or via YouTube. ICUrology provides current and highly relevant knowledge to a broad audience at the cutting edge of urological research and clinical practice.